Reversing Type 2 Diabetes with Bariatric Surgery, Very Low Calorie Diets, and Carbohydrate Restriction: A Review of the Evidence

Published on 
January 25, 2024
April 8, 2019
Sarah Hallberg, DO, MS
Sarah Hallberg, DO, MS
Sarah Hallberg, DO, MS

Type 2 diabetes (T2D) has long been thought of as a progressive, incurable chronic disease, largely because traditional means of treatment have had limited potential to reverse the disease. But newer research exists that suggests reversal is possible through three methods: bariatric surgery, low calorie diets (LCDs), very low calorie diets (VLCDs) and carbohydrate restriction.

I recently published a narrative review of 99 original articles examining the evidence for type 2 diabetes reversal using each of the three reversal methods. We have included the advantages and limitations of each summarized below.

Defining diabetes reversal

We have defined reversal as maintaining an HbA1c below 6.5% without the use of glycemic control medications. We’ve excluded metformin from this criteria because it is not specific to diabetes—many people choose to remain on metformin for reasons other than blood glucose control.

Diabetes reversal is not commonly encouraged by the healthcare system, and reversal is not a goal in the ADA guidelines. The interventions we’ll outline below are generally not the first-line standard of care, and the evidence shows that the standard of care almost never leads to diabetes reversal (1). This raises the question of whether the standard of care is the best practice, and whether reversal methods should be incorporated into the first-line standard of care.

Diabetes reversal intervention 1: Bariatric surgery

The most commonly performed bariatric surgeries in the U.S. include laparoscopic and robotic Roux-en-Y Gastric Bypass (RYGB) or Sleeve Gastrectomy (SG). Anatomically, they both decrease the size of the stomach with RYGB also diverting the small intestine. Bariatric surgery has also been shown to cause alterations in GI hormone releases that may impact eating, hunger, and satiety (2) as well as affect gut microbiota populations (3-9).

Advantages of bariatric surgery:

  • Unilateral improvement in glycemia following operation (10)
  • High rates of T2D remission compared to the non-surgical groups (13)
  • Three-year remission rates of up to 68.7% after RYGB (14)
  • Rapid blood glucose improvements (within hours to days) which likely represents the enteroendocrine responses to altered flow of intestinal contents (i.e., bile acid signaling and changes in microbiota and their metabolome) (15).

Disadvantages of bariatric surgery:

  • Surgery of any type can be associated with complications leading to morbidity or mortality. Complication rates have been stated to be as high as 13% and 21% for SG and RYGB, respectively (16).
  • Significant financial costs for the patient, health system, and insurance companies (U.S. average of $14,389). This cost may be outweighed by medication cost savings—prior to surgery, patients spend over $10,000 per year on diabetes medications, and that cost falls to less than $2,000 per year after surgery. Other analyses show that surgery is likely cost-effective, especially in patients who are obese (17-20).
  • Increased likelihood of long term adverse events. Major adverse events included medication intolerance, need for reoperation, infection, anastomotic leakage, and venous and thromboembolic events (21-25).

Diabetes reversal intervention 2: Low calorie diets (LCDs)

Several studies have reported successful weight loss with decreased insulin resistance and medication use following a LCD or a VLCD.  Total calories per day in studies for VLCDs range from 400-800kcal.  LCDs range from 825-1800 kcal per day and the higher range has been shown to be significantly less effective. Research suggests that LCDs are effective in reversing diabetes in the short term (up to two years), especially in patients with a more recent diabetes diagnosis.

Advantages of LCDs:

  • Quick improvements in glycemic control. A low-calorie diet of 900 kcal, including 115 g of protein, led to significant improvement in glycemic control attributed to improvements in insulin sensitivity (26).
  • Effective in the short term. A VLCD and gastric bypass surgery were equally effective in achieving weight loss and improving glucose and HbA1c levels in obese patients with T2D in the short term (27). DiRECT (Diabetes Remission Clinical Trial), a community-based cluster-randomized clinical trial with 306 relatively healthy participants with T2D (given an 825 kcal/day formula for 3-5 months) found that at one year, 46% of patients met the study criteria of diabetes remission (HbA1c <6.5% without antiglycemic medications). This dropped to 36% at two-years (28,29).

Disadvantages of LCDs and VLCDs:

  • Overall difficult to sustain. In one study, weight loss persisted in the diet-treated patients only for the first three months, indicating difficulties with long-term maintenance (30). Other studies also reported similar pattern of early blood glucose normalization without medication use, but the improvements were not sustained long-term (31-33). One study showed that while a VLCD normalized glucose levels within a week; however at 12 weeks over a quarter of the patients had an early recurrence of diabetes with an average weight regain of 20% (34).
  • Requires substantial caloric restriction. A substantial level of calorie restriction is needed to generate enough weight loss to reverse diabetes. Short-term interventions with moderate energy restriction with metformin (which led to modest weight loss) were less effective in reversing diabetes than standard diabetes care (35).
  • Severe energy restriction may have negative long-term effects. Studies have suggested that the body undergoes physiological and metabolic adaptation in response to caloric restriction, and this may shift one’s energy balance and hormonal regulation of weight toward weight regain after weight loss (36).

Diabetes reversal intervention 3: Carbohydrate restriction

Before insulin was discovered in 1921, low carbohydrate (LC) diets were the standard of care for diabetes (37). With the emergence of exogenous insulin, the goal became to maintain blood sugar control through the use of medications instead of preventing elevations in blood glucose by restricting carbohydrates in the diet. In response to recent studies, the idea of preventing blood sugar elevations with carbohydrate restriction has found its way back into the mainstream standard of care. Low carbohydrate diets have been endorsed by the ADA, the European Association for the Study of Diabetes (EASD), and the Veterans Affairs/ Department of Defense (38-40).

A low carbohydrate diet typically restricts carbs to less than 130 grams per day, and a ketogenic diet to 20-50 grams per day.

Advantages of carbohydrate restriction:

  • Highly effective. In our published trial providing significant support through the use of a continuous care intervention (CCI), we examined using a low carbohydrate diet in patients with T2D (n=262), compared with usual care T2D patients (n=87) (41). At one year, the HbA1c decreased by 1.3% in the CCI, with 60% of completers achieving a HbA1c below 6.5% without hypoglycemic medication (excluding metformin). Insulin was reduced or eliminated in 94% of users. Most cardiovascular risk factors showed significant improvement (41). Improvements were not observed in the usual care patients. Another 34-week trial (43) found that a ketogenic diet intervention (20–50 g net carbs per day) resulted in HbA1c below the threshold for diabetes in 55% of the patients, compared to 0% of patients in the low-fat arm.
  • Does not require calorie restriction. Patients are instructed to carefully restrict dietary carbohydrates, eat protein in moderation, and consume dietary fats to satiety.
  • Sustainable with support. The one-year retention rate in our continuous care intervention was 83%, indicating that a non-calorie-restricted, low carbohydrate intervention can be sustained (41).
  • More cost-effective than bariatric surgery.
  • More effective than restricting overall calories. A study comparing an ad libitum (non-calorie restricted) very low carbohydrate (<20g total) diet to an energy-restricted low-glycemic diet in patients with T2D found a greater reduction in HbA1c, weight, and insulin levels in the low carbohydrate arm (44). 95% of participants in the low carbohydrate arm reduced or eliminated glycemic control medications, compared to 62% in the low glycemic index arm at 24 weeks. A small (34 participants) one-year study of an ad libitum, very low carbohydrate diet compared to a calorie-restricted moderate carbohydrate diet found a significant reduction in HbA1c between groups, favoring the low carbohydrate arm (45).

Disadvantages of carbohydrate restriction:

  • Often requires support. Many of these trials included an educational component, and determining the appropriate method of support may be key to the overall success with disease reversal.
  • Results are promising, but longer-term follow-up studies are needed. Follow up studies have shown sustainability at two years, so longer-term studies are needed to determine the sustainability beyond that.

Are you living with type 2 diabetes, prediabetes, or unwanted weight?

Check to see if your health plan covers Virta
Check Eligibility
  1. Karter AJ, Nundy S, Parker MM, Moffet HH, Huang ES. Incidence of remission in adults with type 2 diabetes: The diabetes & aging study. Diabetes Care (2014) 37: 3188-3195.
  2. Federico, A.; Dallio, M.; Tolone, S.; Gravina, AG.; Patrone, V.; Romano, M.; Tuccillo, C.; Mozzillo, AL.; Amoroso, V.; Misso, G.; Morelli, L.; Docimo, L.; Loguercio, C. Gastrointestinal Hormones, Intestinal Microbiota and Metabolic Homeostasis in Obese Patients: Effect of Bariatric Surgery. In Vivo. 2016, 30,321- 330.
  3. Anhe, FF.; Varin, TV.; Schertzer, JD.; Marette, A. The Gut Microbiota as a Mediator of Metabolic Benefits after Bariatric Surgery. Can J Diabetes. 2017, 41, 439-447.
  4. Medina, DA.; Pedreros, JP.; Turiel, D.; Quezada, N.; Pimentel, F.; Escalona, A.; Garrido, D. Distinct patterns in the gut microbiota after surgical or medical therapy in obese patients. PeerJ. 2017;5:e3443.doi: 10.7717/peerj.3443.
  5. Magouliotis, DE.; Tasiopoulou, VS.; Sioka, E.; Chatedaki, C.; Zacharoulis, D. Impact of Bariatric Surgery on Metabolic and Gut Microbiota Profile: a Systematic Review and Meta-analysis. Obes Surg. 2017, 27, 1345- 1357.
  6. Murphy, R.; Tsai, P.; Jullig, M.; Liu, A.; Plank, L.; Booth, M. Differential Changes in Gut Microbiota After Gastric Bypass and Sleeve Gastrectomy Bariatric Surgery Vary According to Diabetes Remission. Obes Surg. 2017,27,917-925.
  7. Kaska, L.; Sledzinski, T.; Chomiczewska, A.; Dettlaff-Pokora, A.; Swierczynski, J. Improved glucose metabolism following bariatric surgery is associated with increased circulating bile acid concentrations and remodeling of the gut microbiome. World J Gastroenterol. 2016, 22, 8698-8719.
  8. Penney, NC.; Kinross, J.; Newton, RC.; Purkayastha, S. The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. Int J Obes (Lond). 2015, 39, 1565-1574.
  9. Sweeney, TE.; Morton, JM. The human gut microbiome: a review of the effect of obesity and surgically induced weight loss. JAMA Surg. 2013, 148,563-569.
  10. Steven, S.; Carey, PE.; Small, PK.; Taylor, R. Reversal of Type 2 diabetes after bariatric surgery is determined by the degree of achieved weight loss in both short- and long-duration diabetes. Diabet Med. 2015, 32, 47- 53.
  11. Peat, CM.; Kleiman, SC.; Bulik, CM.; Carroll, IM. The Intestinal Microbiome in Bariatric Surgery Patients. Eur Eat Disord Rev. 2015, 23, 496-503.
  12. Sweeney, TE.; Morton, JM. Metabolic surgery: action via hormonal milieu changes, changes in bile acids or gut microbiota? A summary of the literature. Best Pract Res Clin Gastroenterol. 2014, 28, 727-740.
  13. Salminen, P.; Helmio, M.; Ovaska, J.; Juuti, A.; Leivonen, M.; Peromaa-Haavista, P.; Hurme, S.; Soinio, M.; Nuutila, P.; Victorzon, M. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: The SLEEVEPASS randomized clinical trial. JAMA.2018, 319, 241-254.
  14. Purnell, JQ.; Selzer, F.; Wahed, AS.; Pender J, Pories W, Pomp A, et al. Type 2 Diabetes Remission Rates After Laparoscopic Gastric Bypass and Gastric Banding: Results of the Longitudinal Assessment of Bariatric Surgery Study. Diabetes Care. 2016;39:1101-7.
  15. Kaska, L.; Sledzinski, T.; Chomiczewska, A.; Dettlaff-Pokora, A.; Swierczynski, J. Improved glucose metabolism following bariatric surgery is associated with increased circulating bile acid concentrations and remodeling of the gut microbiome. World J Gastroenterol. 2016, 22, 8698-8719.
  16. Ma, IT.; Madura JA. 2nd. Gastrointestinal Complications After Bariatric Surgery. Gastroenterol Hepatol (N Y). 2015, 11, 526-535.
  17. Doble B, Wordsworth S, Rogers CA, et al, What are the real procedural costs of bariatric surgery? A systematic literature review of published cost analyses. Obes Surg. 2017;27(8):2179–2192.
  18. Warren JA, Ewing JA, Hale AL, et al. Cost-effectiveness of bariatric surgery: increasing the economic viability of the most effective treatment for type II diabetes mellitus. The Am Surgeon. 2015;81(8):807–811.
  19. Klein, S.; Ghosh, A.; Cremieux, PY.; Eapen, S.; McGavock, TJ. Economic impact of the clinical benefits of bariatric surgery in diabetes patients with BMI > 35kg/m2. Obesity. 2011, 19, 581-587.
  20. Picot, J.; Jones, J.; Colquitt, JL.; Gospodarevskaya, E.; Loveman, E.; Baxter, L., Clegg, AJ. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess. 2009,13, 1-190.
  21. Rubino F, Schauer PR, Kaplan LM, et al. Metabolic surgery to treat type 2 diabetes: clinical outcome and mechanisms of action. Annu Rev Med. 2010; 61: 393-411.
  22. Abraham A, Ikramuddin S, Jahansouz C, et al. Trends in bariatric surgery: Procedure selection, revisional surgeries, and readmissions. Obesity Surg. 2016; 26(7): 1371-1377.
  23. Tack J, Deloose E. Complications of bariatric surgery: dumping syndrome, reflux and vitamin deficiencies. Best Prac Res Clin Gastroenterol. 2014; 28(4): 741-749.
  24. Eisenbarg D, Azagury DE, Ghiassi S, et al. ASMBS position statement on postprandial hyperinsulinemic hypoglycemia after bariatric surgery. Surg Obes Relat Dis. 2017; 13(3): 371-378.
  25. Bloomberg RD, Fleishman A, Nalle JE, Herron DM, Kini S. Nutritional Deficiencies following Bariatric Surgery: What Have We Learned? Obesity Surgery. 2005; 15:145–154.
  26. Bauman WA, Schwartz E, Rose HG, et al. Early and long term effects of acute caloric deprivation in obese diabetic patients. The Am J Med. 1988;85(1):38–46.
  27. Hughes TA, Gwynne JT, Switzer BR, et al. Effects of caloric restriction and weight loss on glycemic control, insulin release and resistance, and atherosclerotic risk in obese patients with type II diabetes mellitus. The Am J Med. 1984;77(1):7–17.
  28. Lean, MJ.; Leslie, WS.; Barnes, AC.; Brosnahan, N.; Thom, G.; McCombie, L.; Peters, C.; Zhyzhneuskaya, S.; Al-Mrabeh, A.; Hollingsworth, KG.; Rodrigues, AM.; et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018, 391, 541-551.
  29. Lean, MEJ.; Leslie, WS.; Barnes AC.;, Brosnahan, N.; Thom, G.; McCombie, L.; Peters, C.; Zhyzhneuskaya, S.; Al-Mrabeh, A.; Hollingsworth, KG.; Rodrigues, AM.; Rehackova, L.; Adamson, AJ.; Sniehotta, FF.; Mathers, JC.; Ross, HM.; McIlvenna, Y.; Welsh, P.; Kean, S.; Ford, I.; McConnachie, A.; Messow, CM.; Sattar, N.; Taylor, R. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019, doi: 10.1016/S2213-8587(19)30068-3.
  30. Sjostrom L.; Lindroos, AK.; Peltonen, M.; Torgerson, J.; Bouchard, C.; Carlsson, B.; Dahlgren, S.; Larsson, B.; Narbro, K.; Sjostrom, D.; Sullivan, M.; Wedel, H. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004, 351, 2683-2693.
  31. Hughes TA, Gwynne JT, Switzer BR, et al. Effects of caloric restriction and weight loss on glycemic control, insulin release and resistance, and atherosclerotic risk in obese patients with type II diabetes mellitus. The Am J Med. 1984;77(1):7–17.
  32. Hammer S, Snel M, Lamb HJ, et al.. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol. 2008;52(12):1006–1012.
  33. Snel M, Jonker JT, Hammer S, et al. Long-term beneficial effect of a 16-week very low calorie diet on pericardial fat in obese type 2 diabetes mellitus patients. Obesity. 2012;20(8):1572–1576.
  34. Lim, EL.; Hollingsworth, KG.; Aribisala, BS.; Chen, MJ.; Mathers, JC.; Taylor, R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetol. 2011, 54, 2506–2514.
  35. Gregg, EW.; Chen, H.; Wagenknecht, LE.; Clark, JM.; Delahanty, LM.; Bantle, J.; Pownall, HJ.; Johnson, KC.; Safford, MM.; Kitabchi, AE.; Pi-Sunyer, FX.; Wing, RR.; Bertoni, AG.; Look AHEAD Research Group. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012, 308, 2489- 2496.
  36. Fothergill, E.; Guo, J.; Howard, L.; Kerns, JC.; Knuth, ND.; Brychta, R.; Chen, KY.; Skarulis, MC.; Walter, M.; Walter, PJ.; Hall, KD. Persistent metabolic adaptation 6 years after “The Biggest Loser” competition. Obesity. 2016, 24, 1612–1619.
  37. Westman, EC.; Yancy, WS.; Humphreys, M. Dietary treatment of diabetes mellitus in the pre-insulin era (1914-1922). Perspectives in Biology and Medicine. 2006, 49, 77-83.
  38. Davies, MJ.; D’Alessio, DA.; Fradkin, J.; Kernan, WN.; Mathieu, C.; Mingrone, G.; Rossing, P.; Tsapas, A.; Wexler, DJ.; Buse, JB. Management of hyperglycemia in Type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018, 41, 2669-2701.
  39. American Diabetes Association. Summary of Revisions: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019, 42(Suppl 1), S4-S6.
  40. Department of Veteran Affairs and Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Type 2 Diabetes Mellitus in Primary Care. Version 5.0. 2017. doi:10.131410/RG.2.214188.67209.
  41. Hallberg SJ, McKenzie AL, Williams PT, et al. Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year: an open-label, non-randomized, controlled study. Diabetes Ther 2018,9, 583–612.
  42. Bhanpuri NH, Hallberg SJ, Williams PT, et al.. Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at one year: an open label, non-randomized, controlled study. Cardiovasc Diabetol. 2018, 17, 56.
  43. Saslow LR, Mason AE, Kim S, et al. An online intervention comparing a very low-carbohydrate ketogenic diet and lifestyle recommendations versus a plate method diet in overweight individuals with type 2 diabetes: a randomized controlled trial. J Med Internet Res 2017,19:e36.
  44. Westman EC, Yancy WS, Mavropoulos JC, Marquart M, McDuffie JR. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. Nutr Metab. 2008, 19:36. doi:10.1186/1743-7075-5-36.
  45. Saslow LR, Daubenmier JJ, Moskowitz JT, et al. Twelve-month outcomes of a randomized trial of a moderate-carbohydrate versus very low-carbohydrate diet in overweight adults with type 2 diabetes mellitus or prediabetes. Nutrition & Diabetes. 2017, 7:304. doi:10.1038/s41387-017-0006-9.

Frequently Asked Questions

No items found.